hexamethylene bisacetamide has been researched along with Thrombopenia in 4 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 6.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| "The efficacy of hexamethylene bisacetamide (HMBA), a potent polar-planar solvent which is capable of differentiating leukemias and solid tumors in vitro at clinically achievable concentrations, was studied in 16 patients with severe myelodysplastic syndromes (MDS)." | 3.68 | Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. ( Auerbach, M; Conley, BA; Donehower, RC; Jones, RJ; Rowinsky, EK; Spivak, JL, 1992) |
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 2.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| "Hexamethylene bisacetamide was administered as a 5% (w/v) solution via a nasogastric or gastrostomy tube every 4 h for 5 days, followed in 21 days by a 5-day continuous i." | 2.67 | Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube. ( Chun, HG; Kelley, JA; Leyland-Jones, B; Lombardo, FA; Roth, JS; Ward, FT; Weiss, RB, 1991) |
| "6 g/m2/day), we attempted to individualize each patient's dose based on a dosing scheme using an adaptive (feedback) control algorithm, which assumed linear clearance for HMBA." | 1.28 | Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). ( Conley, BA; Egorin, MJ; Forrest, A; Sinibaldi, V; Van Echo, DA; Zuhowski, EG, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M | 1 |
| Stone, R | 1 |
| Michaeli, J | 1 |
| Young, CW | 1 |
| Tong, WP | 1 |
| Sogoloff, H | 1 |
| Ervin, T | 1 |
| Kufe, D | 1 |
| Rifkind, RA | 1 |
| Marks, PA | 1 |
| Rowinsky, EK | 1 |
| Conley, BA | 2 |
| Jones, RJ | 1 |
| Spivak, JL | 1 |
| Auerbach, M | 1 |
| Donehower, RC | 1 |
| Ward, FT | 1 |
| Kelley, JA | 1 |
| Roth, JS | 1 |
| Lombardo, FA | 1 |
| Weiss, RB | 1 |
| Leyland-Jones, B | 1 |
| Chun, HG | 1 |
| Forrest, A | 1 |
| Egorin, MJ | 1 |
| Zuhowski, EG | 1 |
| Sinibaldi, V | 1 |
| Van Echo, DA | 1 |
2 trials available for hexamethylene bisacetamide and Thrombopenia
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
Topics: Acetamides; Adolescent; Adult; Aged; Bone Marrow; Cell Differentiation; Hematopoietic Stem Cells; Hu | 1992 |
Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Topics: Acetamides; Adult; Aged; Biological Availability; Confusion; Drug Evaluation; Female; Gastrointestin | 1991 |
2 other studies available for hexamethylene bisacetamide and Thrombopenia
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Topics: Acetamides; Adult; Aged; Algorithms; Cell Division; Depression, Chemical; Drug Administration Schedu | 1992 |
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Topics: Acetamides; Algorithms; Antineoplastic Agents; Drug Evaluation; Humans; Neoplasms; Thrombocytopenia | 1989 |